For decades, diabetic macular edema (DME) has been one of the stealthier threats to the vision of people with diabetes—an often gradual but devastating swelling of the retina’s center that, left unchecked, can blur or even steal sight entirely. But a new glimmer of hope has emerged, and it comes from an unexpected source: an inexpensive antiretroviral pill long used to treat HIV.
In a small but compelling clinical trial published in Med, researchers at the University of Virginia report that lamivudine, a well-known HIV medication, may help restore vision in patients with DME. Unlike the current standard of care, which involves injecting anti-VEGF drugs directly into the eye—a procedure as unpleasant as it sounds—lamivudine is taken orally and, remarkably, could offer comparable or even superior results.
“This could be a game-changer,” said Dr. Jayakrishna Ambati, the study’s senior author and founding director of UVA Health’s Center for Advanced Vision Science. “Not only is it easier for patients, but it could dramatically reduce the burden on the health care system.”
The study involved 24 individuals diagnosed with DME. Over an eight-week period, half received lamivudine pills while continuing their regular injections of bevacizumab, a standard anti-VEGF therapy. The other half received placebo pills alongside the same injections.
The results were striking: by the four-week mark, patients on lamivudine could read nearly 10 more letters on an eye chart than at baseline. By week eight, that number jumped to 17 letters, equating to more than three lines of regained vision. In comparison, the placebo group showed only modest gains, despite receiving the same injectable treatment.
Why would an HIV drug work for an eye condition rooted in diabetes? The answer lies in inflammation. Lamivudine blocks inflammasomes—molecular triggers of the immune system known to stoke inflammation throughout the body. These inflammasomes play a central role in the progression of DME, making lamivudine a surprising but well-matched candidate.
What’s more, the cost difference is dramatic. Lamivudine runs around $20 per month, while monthly eye injections can soar to $2,000—not to mention the logistical hurdles and stress associated with regular intravitreal procedures.
Still, Ambati and his team are cautious. “These are early days,” he emphasized. The sample size was small, and patients were only tracked for two months. Larger, longer-term trials will be needed to confirm the drug’s efficacy and determine whether these gains can be sustained or improved over time.
Looking ahead, the team is also exploring a novel, safer derivative of lamivudine known as K9, which may offer the same benefits without some of the antiretroviral’s potential side effects. Clinical trials of K9 in DME are already in motion.
The implications are enormous. More than 1 in 14 people with diabetes will develop DME, and many lack access to expensive or invasive treatments. If a simple oral therapy can achieve comparable results, it could fundamentally shift how this common complication is managed—making treatment not only more accessible, but significantly less invasive.
In a field often characterized by high costs and high-tech solutions, lamivudine offers a rare thing: an off-the-shelf answer hiding in plain sight. Sometimes, innovation isn’t about what’s new—it’s about seeing old tools in a new light.
